PDS Biotechnology (NASDAQ:PDSB – Get Rating)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They presently have a $21.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 170.62% from the company’s current price.
Several other research firms also recently commented on PDSB. Noble Financial raised their price objective on PDS Biotechnology to $19.00 in a research note on Monday, November 28th. B. Riley lifted their target price on PDS Biotechnology from $10.00 to $12.00 in a research report on Wednesday, December 28th. Finally, Chardan Capital boosted their target price on PDS Biotechnology from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday, November 14th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.80.
PDS Biotechnology Trading Up 1.4 %
NASDAQ PDSB opened at $7.76 on Tuesday. The company has a quick ratio of 15.37, a current ratio of 15.37 and a debt-to-equity ratio of 0.49. The stock’s 50 day moving average is $9.49 and its 200 day moving average is $7.02. PDS Biotechnology has a twelve month low of $2.89 and a twelve month high of $13.65. The firm has a market capitalization of $220.85 million, a PE ratio of -7.68 and a beta of 2.23.
Institutional Trading of PDS Biotechnology
About PDS Biotechnology
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection.
- Get a free copy of the StockNews.com research report on PDS Biotechnology (PDSB)
- Jack in the Box Pops On Tasty Results, Robust Outlook
- How Low Can Lowe’s Companies Go?
- Ambarella: An AI Play In The Making
- Wendy’s Price Firms After Sizzling Quarter And Juicy Outlook
- Terran Orbital’s New $2.4 Billion Contract is a Game Changer
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.